Anti-GPC3 Targeted Therapies: Target Population, Competitive Landscape

As a leading expert in life sciences market research, I'm excited to delve into DelveInsight’s detailed report on Anti-GPC3 Targeted Therapies. This innovative area targets Glypican-3 (GPC3), a protein overexpressed in cancers like hepatocellular carcinoma (HCC), offering new hope for precision treatments. In this LinkedIn article, I'll cover the target population, competitive landscape, and market forecast to 2040 across the 7MM (US, EU4, UK, Japan).

Anti-GPC3 Targeted Therapies Market Overview and Projections

The Anti-GPC3 Targeted Therapies market in the 7MM is projected to grow at a significant CAGR by 2034 in leading countries (US, EU4, UK, and Japan). The total market for anti-GPC3 targeted therapies in the 7MM is projected to expand dramatically, reaching approximately USD 3.2 billion by 2040, up from USD 24 million in 2032. This rapid growth reflects the increasing clinical adoption of next-generation GPC3 therapies, rising incidence of GPC3-expressing malignancies, and the anticipated introduction of first-in-class approvals. Anti-GPC3 therapies harness tumor-specific GPC3 expression to induce direct cytotoxicity, block oncogenic signaling pathways, and enhance immune-mediated tumor elimination. Their effectiveness depends on factors such as tumor type, GPC3 expression levels, and the tumor microenvironment, positioning them as promising approaches for Hepatocellular Carcinoma (HCC) and other GPC3-positive cancers.

DelveInsight’s “Anti-glypican-3 (GPC3) Targeted Therapies – Target Population, Competitive Landscape, and Market Forecast – 2040” report delivers an in-depth understanding of the anti-GPC3 targeted therapies, historical and projected epidemiological data, competitive landscape as well as anti-GPC3 targeted therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Request for a Free Sample Report @ Anti-GPC3 Targeted Therapies Market Forecast

Some facts of the Anti-GPC3 Targeted Therapies Market Report are:

• According to DelveInsight, Anti-GPC3 Targeted Therapies market size is expected to grow at a significant CAGR by 2040.

• According to DelveInsight’s analysis, the Anti-GPC3 Targeted Therapies Market in the 7MM was valued at approximately USD 24 million in 2032. Over the forecast period from 2025 to 2040, this Anti-GPC3 Targeted Therapies Market is projected to reach USD 3.2 billion.

• Leading Anti-GPC3 Targeted Therapies companies working in the market are RayzeBio/Bristol Myers Squibb, AstraZeneca, BeOne Medicine, Eureka Therapeutics, Sotio Biotech, Zymeworks, Bayer, and others.

• Key Anti-GPC3 Targeted Therapies Therapies expected to launch in the market are RYZ801, AZD9793, BGB-B2033 ± Tislelizumab, ECT204, BOXR1030, ZW251, 225Ac-GPC3 (BAY 3547926), and others.

• The Anti-GPC3 Targeted Therapies market is expected to surge due to the increasing prevalence of GPC3-expressing cancers and the launch of innovative therapies during the forecast period. Furthermore, multiple-stage Anti-GPC3 Targeted Therapies pipeline products will significantly revolutionize the Anti-GPC3 Targeted Therapies market dynamics.

• In January 2025, PeptiDream announced that RayzeBio, a Bristol Myers Company, has initiated a Phase I/Ib clinical trial of RYZ801 and RYZ811.

• In June 2025, AstraZeneca presented new data from its oncology pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting AZD9793 for GPC3+ advanced HCC.

• In 2024, BeOne Medicine advanced BGB-B2033 ± Tislelizumab for GPC3+ unresectable HCC.

• In March 2024, Eureka Therapeutics progressed ECT204 for GPC3-positive solid tumors.

• In February 2024, Sotio Biotech initiated BOXR1030 trials for advanced HCC.

Anti-GPC3 Targeted Therapies Overview

Anti-GPC3 targeted therapies have evolved from monoclonal antibodies to next-generation approaches such as antibody-drug conjugates, multispecific/bispecific antibodies, radiopharmaceuticals, and CAR-T cell therapies. GPC3 is a cell-surface proteoglycan highly expressed in HCC but absent in normal liver tissue, making it a promising diagnostic biomarker and therapeutic target. Its role in key oncogenic pathways, including Wnt/ß-catenin and Hedgehog signaling, drives tumor growth. Measuring GPC3 via biopsy has limitations due to invasiveness and tumor heterogeneity. Early clinical studies show manageable safety and preliminary activity, while molecular delivery systems and targeted radionuclides aim to enhance efficacy and overcome resistance. Successful translation relies on precise patient selection, combination strategies with immunotherapy, and overcoming the immunosuppressive tumor microenvironment.

Do you know what will be the Anti-GPC3 Targeted Therapies market share in 7MM by 2040 – Anti-GPC3 Targeted Therapies Market Dynamics and Trends

Anti-GPC3 Targeted Therapies Market

In 2032, the anti-GPC3 targeted therapies market across the 7MM was valued at USD 24 million, with the U.S. contributing significantly. The EU4 and the UK generated substantial shares, while Japan accounted for a smaller portion. Emerging therapies dominated the market, with ADCs and radiopharmaceuticals leading. Key companies—including RayzeBio, AstraZeneca, BeOne Medicine, and Sotio Biotech—are driving innovation, supporting a projected high CAGR from 2025 to 2040.

Market growth is fueled by advancements in targeted modalities aimed at GPC3-expressing tumors. Current approaches include monoclonal antibodies and ADCs, while pipeline therapies such as RYZ801 and AZD9793 target immune activation and radionuclide delivery. Combination with immunotherapy remains vital for enhancing responses.

Despite progress, gaps persist due to limited approved therapies and challenges in patient stratification. Nonetheless, ongoing research indicates strong potential for GPC3-targeted treatments to transform oncology.

Anti-GPC3 Targeted Therapies Epidemiology

According to DelveInsight, the target population for Anti-GPC3 Targeted Therapies includes patients with GPC3-expressing cancers. GPC3 expression is observed in approximately 75% of hepatocellular carcinoma (HCC) cases and 70% of Merkel cell carcinoma (MCC) cases, reinforcing its role as a key biomarker. In 2024, HCC accounted for the largest GPC3-expressing patient population in the US with approximately 25,000 cases, while Japan reported approximately 7,800 HCC cases. This underscores regional differences in disease incidence and the need to adapt GPC3-targeted therapeutic strategies.

Anti-GPC3 Targeted Therapies Epidemiology Segmentation:

• Total Incident Cases of Promising Indications

• GPC3 Expressing Incident Cases of Selected Indications

• GPC3 Expressing Locally Advanced/Metastatic Cases

• GPC3 Biomarker Positive Advanced/Metastatic Cases

Interested to know how the emerging diagnostic approaches will be contributing in increased Anti-GPC3 Targeted Therapies target population pool? Download report – Anti-GPC3 Targeted Therapies Patient Pool Forecast

Anti-GPC3 Targeted Therapies Pipeline Development Activities and Drugs Uptake

RYZ801 – RayzeBio/Bristol Myers Squibb
RYZ801 is a first-in-class proprietary peptide that specifically binds to GPC3 to deliver Ac225 for the treatment of HCC. RYZ801 is currently being investigated in a Phase I/Ib trial to evaluate its safety. Preclinical biodistribution studies demonstrated strong tumor uptake and sustained retention, with minimal accumulation in normal tissues.

AZD9793 – AstraZeneca
AZD9793 is a first-in-class, trispecific IgG1 monoclonal antibody that functions as a CD8-targeted T-cell Engager (TCE). It simultaneously binds tumor-infiltrating T cells and GPC3-positive tumor cells, forming a bridge that triggers T-cell activation, tumor cell killing, and T-cell proliferation.

Anti-GPC3 Targeted Therapies Competitive Landscape

The Anti-GPC3 Targeted Therapies report provides insights into different therapeutic candidates in Phase I, Phase I/II, and early stages. It also analyses Anti-GPC3 Targeted Therapies key players involved in developing targeted therapeutics.

Anti-GPC3 Targeted Therapies Companies and Drugs

• RYZ801: RayzeBio/Bristol Myers Squibb

• AZD9793: AstraZeneca

• BGB-B2033 ± Tislelizumab: BeOne Medicine

• ECT204: Eureka Therapeutics

• BOXR1030: Sotio Biotech

• ZW251: Zymeworks

• 225Ac-GPC3 (BAY 3547926): Bayer

Download report to know which TOP 3 therapies will be capturing the largest Anti-GPC3 Targeted Therapies market share by 2040? Click here – Anti-GPC3 Targeted Therapies Treatment Market

Anti-GPC3 Targeted Therapies Therapeutics Assessment

Major key companies are working proactively in the Anti-GPC3 Targeted Therapies Therapeutics market to develop novel therapies which will drive the Anti-GPC3 Targeted Therapies treatment markets in the upcoming years are RayzeBio/Bristol Myers Squibb, AstraZeneca, BeOne Medicine, Eureka Therapeutics, Sotio Biotech, Zymeworks, Bayer, and others.

Anti-GPC3 Targeted Therapies Clinical Trials
The report delves into ongoing and upcoming clinical trials for Anti-GPC3 Targeted Therapies, highlighting trial designs, patient recruitment, endpoints, and key results from studies evaluating therapies like RYZ801 and AZD9793.

Anti-GPC3 Targeted Therapies Companies
Leading entities include RayzeBio/Bristol Myers Squibb, AstraZeneca, BeOne Medicine, Eureka Therapeutics, Sotio Biotech, Zymeworks, Bayer, and others, each advancing targeted treatments for GPC3-positive cancers.

Anti-GPC3 Targeted Therapies Drugs
Key therapies encompass RYZ801, AZD9793, BGB-B2033 ± Tislelizumab, ECT204, BOXR1030, ZW251, 225Ac-GPC3 (BAY 3547926), and others, focusing on direct cytotoxicity and immune enhancement.

Do you know how RYZ801 and AZD9793 market launch will be impacting the Anti-GPC3 Targeted Therapies market CAGR? Download sample report - Anti-GPC3 Targeted Therapies Clinical Trials and Drugs Market

Anti-GPC3 Targeted Therapies Report Key Insights

1. Anti-GPC3 Targeted Therapies Target Population

2. Anti-GPC3 Targeted Therapies Market Size and Trends

3. Key Cross Competition in the Anti-GPC3 Targeted Therapies Market

4. Anti-GPC3 Targeted Therapies Market Dynamics (Key Drivers and Barriers)

5. Anti-GPC3 Targeted Therapies Market Opportunities

6. Anti-GPC3 Targeted Therapies Therapeutic Approaches

7. Anti-GPC3 Targeted Therapies Pipeline Analysis

8. Anti-GPC3 Targeted Therapies Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Anti-GPC3 Targeted Therapies Market

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Content Us

Kanishk

kkumar@delveinsight.com